Type 1 diabetes diagnosis is missed less frequently when patients present during childhood or adolescence, but unlike in adults, misdiagnosis in childhood is associated with an increased likelihood of diabetic ketoacidosis.
The FDA has granted Breakthrough Therapy designation to teplizumab (PRV-031; Provention Bio), for the prevention or delay of clinical T1D in those at risk of developing the disease.
In young patients with type 1 diabetes, phenotypes of body mass index and glycemic control are associated with patterns of early diabetes complications.
Researchers aimed to determine the optimal BP threshold to minimize the risk for coronary artery disease events in young patients with childhood-onset T1D.
Measurement of serum apolipoprotein levels in apolipoprotein-defined lipoprotein subclasses may have an important role in predicting vascular complications in T1D.
There is a correlation between a high level of amyloid-producing Escherichia coli in the intestines and the initiation of autoimmunity and type 1 diabetes progression.
Patients who attended complication screenings paid more visits to diabetes clinics within the first 2 years after diagnosis, had higher median lifetime HbA1c, and had less socioeconomic disadvantage.
